Log in to save to my catalogue

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acut...

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acut...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_522914dd6cf246468f2f5d959f5f9ca1

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

About this item

Full title

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

Publisher

England: BioMed Central Ltd

Journal title

Journal of hematology and oncology, 2022-12, Vol.15 (1), p.171-26, Article 171

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognosis of about 30%. Therefore, the development of more effective therapeutics with novel mode of action is urgently demanded. One common mutated...

Alternative Titles

Full title

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_522914dd6cf246468f2f5d959f5f9ca1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_522914dd6cf246468f2f5d959f5f9ca1

Other Identifiers

ISSN

1756-8722

E-ISSN

1756-8722

DOI

10.1186/s13045-022-01390-5

How to access this item